Objective: Higher latitude, lower ultraviolet exposure, and lower serum 25-hydroxyvitamin D (25OHD) correlate with higher multiple sclerosis (MS) prevalence, relapse rate, and mortality. We therefore evaluated the effects of high-dose vitamin D2 (D2) in MS.
Vitamin D is synthesized after ultraviolet exposure 1 and vitamin D nutrition is measured by serum 25-hydroxyvitamin D (25OHD). 1 Lower ultraviolet exposure and lower 25OHD correlate directly with MS prevalence, relapses, and mortality, [2] [3] [4] [5] [6] [7] [8] although this is not universally found, 9, 10 and indirectly with active MS lesions on brain MRI. 11, 12 Autoimmune mechanisms contribute to experimental autoimmune encephalomyelitis (EAE) and are implicated in relapsing-remitting MS (RRMS) 13, 14 and vitamin D metabolites suppress the pathogenic immune responses characteristic of autoimmune diseases 8, 15 and prevent or ameliorate EAE. 16 Oral vitamin D3 in the form of cod liver oil (5,000 IU/day) reduced relapse rate in an uncontrolled MS trial 17 and high-dose vitamin D3 appeared to retard progression of MS-related disability in an un-blinded study. 18 When 1,25-dihydroxyvitamin D [1, 25(OHD) 2 D], a potent metabolite for calcium mobilization, was administered to people with MS, 4 of 15 required dose adjustment or withdrew due to hypercalcemia. 19 A 1, 25(OH) 2 D precursor (alfacalcidol) was, however, well-tolerated in an uncontrolled trial of 5 people with MS. 20 A 1,25(OH) 2 D analog which is less likely to induce hypercalcemia was not beneficial for people with MS. 21 That analog was not directly efficacious in EAE and the relevance of that trial to the potential efficacy of plain oral vitamin D in MS is equivocal. 22 There is no randomized controlled trial (RCT) comparing high-dose vitamin D2 or D3 to low-dose supplementation in MS.
METHODS Primary research question. We performed a double-blind RCT in RRMS to examine whether adding high-dose oral vitamin D2 reduced MRI indices of disease activity in comparison with ongoing low-dose supplementation (level 1 evidence) and to provide effect size estimates for larger definitive RCTs.
Participants. Inclusion criteria. Inclusion criteria were RRMS (McDonald criteria 23 ), age Ͼ18 years, relapse within the preceding 24 months despite immunomodulatory therapy, or declined or could not tolerate such therapy.
Exclusion criteria. Exclusion criteria were primary or secondary progressive MS, pregnancy, clinical relapse or systemic glucocorticoid therapy within the prior 30 days, Expanded Disability Status Scale (EDSS) 24 25 with coefficient of variation (CV) at median 32, 60, and 117 nM of 9.5%, 9.5%, and 9.0%. PTH was measured by Immulite 2000 Intact (Siemens Los Angeles, CA); CV at median 3.4, 30, and 98 pM was 8%, 8%, and 7.5%. Calcium, albumin, uric acid, and creatinine were measured on an Olympus 2700 (Olympus, Tokyo).
Age, sex, medications, date of diagnosis, relapses in the past 24 months, and EDSS were documented by 1 of 2 blinded assessing neurologists.
Form of vitamin D. Oral vitamin D increases serum 25OHD
without elevating serum 1,25(OH) 2 D or inducing hypercalcemia or hypercalciuria. 18, 26, 27 Humans may metabolize circulating 25OHD to active autocrine/paracrine tissue vitamin D metabo-lites, with a substrate to product conversion efficiency approaching 80% 8, 28 and enzymes for this metabolism are present in the CNS. 29 As 25OHD circulates at nanomolar concentrations, a plain oral vitamin D supplement to elevate serum 25OHD may therefore lead to nanomolar tissue concentrations of vitamin D metabolites [including 1,25(OH) 2 D] for autocrine and paracrine activity. Conversely, oral 1,25(OHD) 2 D and its analogues are limited by hypercalcemia and hypercalciuria when present at only picomolar serum concentrations. If exogenous vitamin D is indeed efficacious in MS, then plain oral vitamin D may have greater efficacy, with less toxicity, than oral 1,25(OH) 2 D or its analogues. 22 The 2 common choices for plain vitamin D supplementation are vitamin D2 or vitamin D3. Vitamin D2 was chosen because of its success in an RCT of falls prevention, demonstrating extraskeletal efficacy on neural or muscular function 30 ; its additional metabolic pathway through serum 24OHD 31 that could offer additional benefit for any given serum level of 25OHD; and its plant origin that minimizes risk of transmissible disease. In chronic low-dose administration (as opposed to single acute dosing), vitamin D2 is as efficacious as vitamin D3 in elevating serum 25OHD, 32 although whether this occurs with chronic high-dose supplementation is not known.
Treatment: High-dose vitamin D2. High-dose vitamin D2
(6,000 IU) was given in a vegetable capsule, custom formulated by Cardinal Health (Braeside, Victoria). Placebo capsules had the same formulation minus vitamin D2.
The initial dose of high-dose vitamin D2 was one high-dose capsule twice a day after food. Venipuncture was performed at 2 and 4 weeks and monthly thereafter to measure serum 25OHD. Each subject's capsule dose was adjusted empirically in the light of their serial venipuncture results to maintain their 25OHD, with a target range of 130 -175 nM. One investigator was unblinded to advise study nurses of dose adjustments. Nurses remained blinded and contacted participants.
Treatment protocol. Randomization. Participants were recruited in 5 groups. Each group was subject to computer randomization by an off-site statistician blocking on specific MS therapy (glatiramer acetate, interferon, no specific therapy), except for the first 2 participants who were computer randomized by the unblinded investigator as the statistician was unavailable. Subjects within each group commenced randomized treatment at the same time, controlling for season.
In a separate random allocation, each participant on highdose vitamin D2 was paired with a "buddy" on placebo. With every change in high-dose D2 capsule dose, the buddy was contacted by a study nurse to make the same capsule dose change.
Low-dose vitamin D2. It was considered unethical to withhold low-dose D because of its putative benefit. Therefore all participants also received one capsule of low-dose (1,000 IU) vitamin D2 daily throughout randomized treatment (Ostelin capsule, Boots, North Ryde, NSW).
The manufacturer changed production to an otherwise identical 1,000 IU vitamin D3 capsule after trial commencement. We could not source the vitamin D2 version when our final 3 participants (2 on high-dose D2 and 1 on placebo high-dose) were 3 months from exit. We monitored their 25OHD and in their final month supplied all 3 with the vitamin D3 capsule daily to prevent vitamin D deficiency (defined as serum 25OHD Ͻ25 nM) for which one was then at risk. Treatment groups. One group (high-dose D2) received 1,000 IU vitamin D2 daily plus a high-dose vitamin D2 supplement. The other group (low-dose D2) received 1,000 IU vitamin D2 daily plus a placebo supplement.
Time course. Time course was 6 months, to allow time to elevate and maintain 25OHD for a period consistent with the apparent latency of effect observed in epidemiologic studies. 11, 12 Brain MRI. Brain MRI at baseline, 4, 5, and 6 months was performed using a 3 T Siemens Magnetom Trio TIM scanner (Erlangen, Germany). Imaging sequences acquired for this study included 2 3-dimensional T1-weighted sequences, one acquired preinjection and one acquired postinjection with gadopentetate dimeglumine (0.1 mmol/kg, up to maximum of 20 mL of Gadovist © , Bayer Schering Pharma AG, Berlin, Germany). Three sets of conventional contrast MRI images were acquired using 3-dimensional sequences for lesion identification. Precontrast and postcontrast T1-weighted images were obtained with the following parameters: repetition time (TR) ϭ 1,900 msec, echo time (TE) ϭ 2.15 msec, inversion time (TI) ϭ 900 msec, flip angle (FA) ϭ 9°, slice thickness ϭ 1 mm, matrix size ϭ 256 ϫ 215, field of view (FOV) ϭ 224 ϫ 256 mm 2 . Before contrast was administered, T2-weighted images were acquired with the following parameters: TR ϭ 3,200 msec, TE ϭ 579 msec, FA ϭ 120°, slice thickness ϭ 1 mm, matrix size ϭ 320 ϫ 288, FOV ϭ 243 ϫ 270 mm 2 . Scans were encoded to preserve blinding. The first 2 patients were scanned on a 1.5 T closed scanner (General Electric Echospeed HDX, Milwaukee, WI) prior to availability of the 3 T scanner and received triple dose gadolinium (Magnevist [dimeglumine gadopentetate], Bayer Schering Pharma AG, Germany). Subsequently, standard dose gadolinium was used due to emerging concerns regarding nephrogenic systemic fibrosis.
Blinded reading. Two blinded study neuroradiologists evaluated scans to determine gadolinium-enhancing (GE) lesions. One also determined total volume of T2 lesions (baseline and 6 months) with a neuroradiology research scientist using semiautomated software (MRICRO [www.mricro.com]).
Biochemical monitoring. Creatinine and eGFR at 4, 5, and 6 months and calcium, albumin, uric acid, and PTH at 3 and 6 months were monitored.
Clinical monitoring. Neurologists were blinded to treatment allocation. EDSS was assessed at baseline and at 6 months or early exit visit. Relapses were defined by one of the participating neurologists as the development of new neurologic symptoms and signs at least 30 days after onset of last relapse (McDonald criteria 27 ). Participants attended for relapse confirmation with the assessing neurologist. Endpoints. Primary endpoints were the cumulative number of new GE lesions and change in the total volume of T2 lesions. Secondary endpoints were the change in EDSS and the number of clinical relapses.
Statistics. Differences between cohorts were tested by Mann-
Whitney or Kruskal-Wallis tests. For primary endpoints, a pure randomization test tested the significance of the difference (highdose minus low-dose) of the mean cumulative number of new GE per person. The 95% confidence interval (CI) for the difference in mean cumulative number of new GE per person was calculated by bootstrap analysis. For secondary endpoints, ordinal logistic regression tested for a treatment effect on exit EDSS. Entry EDSS was entered as a series of dummy variables to reflect the ordinal nature of this variable. This method gives the odds ratio (OR) (95% CI) for a lower exit EDSS with high-dose compared to low-dose vitamin D2. The Fisher exact test determined the significance of the difference in proportions having relapse between the high-dose and low-dose cohorts. The 95% CIs for the difference in percentage experiencing relapse were calculated using the Newcombe-Wilson score method (corrected) as an approximation. 33 Analyses were intention to treat (with last observation carried forward for GE and relapses). Separate completers analyses considered only those for whom there were 6-month data. Analyses were performed using Minitab versions 13 and 16 (www.minitab.com) and Poptools (www.poptools.org). 34 A 2-tailed p value Ͻ0.05 was considered significant. There were no previous RCT data from which to estimate highdose added to low-dose vitamin D2 effect. No power calculation was attempted. An a priori trial aim was to generate data helpful for larger definitive trial power calculations.
RESULTS Participant progress through trial.
Twenty-five volunteers passed screening. Two withdrew before randomization (figure 1). Eleven were randomized to high-dose vitamin D2, 12 to low-dose vitamin D2. There were 3 withdrawals: 1 at 2 weeks with nausea (low-dose group), 1 after 4 months to electively enter a different MS trial (low-dose group), and 1 after relapse at 3 months in order to receive natalizumab (high-dose group). The latter 2 had exit MRI and EDSS. The first subject started treatment Other biochemistry. There were no significant changes in PTH, calcium, corrected calcium, albumin, uric acid, creatinine, or eGFR during the study in either group.
Gadolinium-enhancing lesions. Baseline. Seven participants had baseline GE. Of these, 4 were randomized to high-dose (1, 1, 3, and 38 lesions) and 3 to lowdose D2 (2, 3, and 5 lesions). Baseline 25OHD was not significantly different between participants with and without baseline GE lesions with respective medians (IQR) of 61 (33-74) vs 56 (42-61) nM.
New GE lesions. Six participants developed new lesions. Of these, 5 had at least one GE lesion at baseline. The sixth (high-dose D2) developed new GE at all timepoints (table 2) .
There was no significant difference between treatment groups in the cumulative number of new GE lesions, 14 (high-dose) vs 11 (low-dose), or the number of people with new GE lesions (tables 2 and 3). One participant (low-dose) missed the 5-month scan. T2 volume. Baseline. The baseline volume of lesions on T2-weighted imaging for the entire trial cohort did not correlate with 25OHD, PTH, or corrected calcium. Treatment. There was no difference in the change in total volume of T2 lesions according to treatment ( p ϭ 0.6): median (IQR) changes Ϫ330 (Ϫ950 to Ϫ30) for high-dose vs Ϫ95 (Ϫ310 to Ϫ25) mm 3 for low-dose (table 3) .
One participant (low-dose) had brain surgery during study for an unrelated lesion and was excluded from all T2 analyses as removed tissue included T2 lesions.
EDSS. Median (IQR) exit EDSS was higher in the high-dose group: 3 (2-4) vs 2 (1-2) in the low-dose group ( p ϭ 0.04). Exit EDSS correlated with entry EDSS (r ϭ 0.79, p Ͻ0.001). In ordinal logistic regression that adjusted for entry EDSS, treatment with high-dose vitamin D2 was marginally associated with a higher exit EDSS ( p ϭ 0.051) (table 3) .
Relapses. Of 11 people randomized to high-dose vitamin D2, 4 (36.5%) had a relapse. Two were already on stable therapy with interferon-␤, one on glatiramer acetate. Three received IV methylprednisolone approximately 5 weeks, 4 months, and 6 months into study. The fourth was withdrawn and commenced on natalizumab at the 3-month timepoint. Of 12 randomized to low-dose vitamin D2, none had relapse ( p ϭ 0.04 for the difference in proportions having relapse) (see table 3 ).
Two who developed relapse had baseline GE and also developed new GE lesions. No GE lesions were detected in the other 2 who developed relapse. Potential outlier. A participant with 38 baseline GE lesions and relapse at 5 weeks was excluded and endpoints reanalyzed (table 3) . Treatment with highdose vitamin D2 was no longer associated with higher exit EDSS ( p ϭ 0.092) or relapse ( p ϭ 0.08). DISCUSSION This trial tested for a benefit of highdose vitamin D2 over low-dose in people with clinically active RRMS. There was no between-group difference in the primary MRI-based outcome mea- Table 2 Gadolinium-enhancing lesions sures. However, there was a higher exit EDSS and a higher proportion exhibiting relapse with high-dose vitamin D2. Changes in response to diseasemodifying therapy in several subjects could account for the minor differences noted between the highdose and low-dose groups, and this possibility cannot be ruled out on present data. These clinical outcomes, in the absence of worse MRI endpoints, need confirmation in larger trials. However, high-dose vitamin D2 does not appear to be of benefit in RRMS, especially by the most informative and reliable measure, MRI.
In contrast, an MS study using vitamin D3 reported a smaller proportion of subjects treated with high-dose vitamin D3 had worsening EDSS ( p ϭ 0.019) and a smaller proportion relapse ( p ϭ 0.09). 18 However, that study was not blinded and did not adjust for baseline EDSS. Additionally, subjects not receiving high-dose vitamin D3 were permitted up to 4,000 IU vitamin D daily, confounding the comparison. Another group found the mean number of GE lesions fell after high-dose D3 supplementation, but that was an uncontrolled unblinded study. 27 In theory, vitamin D supplementation could be detrimental if it increased expression of HLA DRB1*15, 7,35 a protein isoform associated with increased risk for MS. Against this, people with MS who had the HLA DRB1*15 genotype did not have worse clinical outcome in association with higher serum 25OHD. 7 In another study daily 1,000 IU vitamin D3 increased serum levels of an inflammatory cytokine in people with MS. 36 However, in our 6-month study the entire low-dose group, which received 1,000 IU vitamin D2 daily, had no relapses and only 3 of 12 participants taking low-dose vitamin D2 developed new GE lesions.
We found no association between baseline serum 25OHD and the presence of GE lesions or the total volume of T2 lesions, consistent with other data. 6,10. In T cells, T-cell lines, and dendritic cells derived from people with RRMS and healthy people, 10 nM 1,25(OH) 2 D altered cell behavior toward a less pathogenic and more tolerogenic phenotype. 8 The relevance of this has been questioned because the tested 1,25(OH) 2 D concentration far exceeds serum levels. 37 However, similar concentrations could theoretically be achieved in CNS tissue after autocrine metabolism of nanomolar levels of circulating serum 25OHD. The serum 25OHD of our low-dose cohort rose from 54 nM to 69 nM. Raw data from a cross-sectional study 38 suggest higher T-cell regulatory activity and less Th1:Th2 bias in people with RRMS at higher serum 25OHD up to levels of 50 -70 nM, above which little further difference is apparent.
Correlations of lower MS prevalence, activity, and mortality with high levels of vitamin D3 nutrition have led to the hypothesis that high levels of vitamin D could be beneficial for MS. Our RCT outcomes do not support this hypothesis. A limitation of our trial is that our sample was selected for ongoing disease activity. Trials of primary prevention or conducted at earlier stages of disease, such as first demyelinating event, may find different outcomes as may larger trials, trials of vitamin D3, or trials that vary serum 25OHD more slowly. 39 A trial that restricted enrollment to MS treatment-naive subjects could more clearly test a vitamin D2 benefit, how- ever, inclusion of people already taking glatiramer acetate or interferon increases the clinical generalizability. It is also possible that any vitamin D benefit for MS occurs with low-level supplementation and oral vitamin D beyond that does not provide additional benefit. If this is the case, then epidemiologic correlations of better MS outcomes with higher serum 25OHD may simply reflect the identification of people with MS who have a low probability of experiencing vitamin D deficiency. 40 In conclusion, in people with clinically active RRMS taking 1,000 IU of vitamin D2 per day, we did not find a therapeutic advantage from additional high-dose vitamin D2.
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